This examines complementary mechanisms since anti-CD200 therapies deplete immunosuppressive signals within the tumor microenvironment and amplify immune-mediated tumor attacks, while CDK4/6 inhibitors block tumor proliferation via the induction of G1 cell cycle arrest [1]. The gene discussed is CDK4; the disease is neoplasm.